Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in HR+/HER2– metastatic breast cancer. In this educational program, these experts discuss the latest advances in integrating oral SERDs and emerging combination strategies into the care of patients with HR+/HER2– metastatic breast cancer. Through interactive, case-based discussions, participants gain practical strategies for treatment selection and sequencing, choosing between monotherapy and combination approaches based on patient-specific factors, applying clinical trial and real-world evidence, and proactively managing adverse events to optimize patient outcomes.

This educational activity is an archive of the live presentation held on July 23, 2026.

Target Audience

This educational program is primarily directed toward a global audience of community-based medical oncologists, surgical oncologists, advanced practice providers, nurses, and other healthcare providers involved in the treatment of metastatic breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Identify approved and emerging oral SERDs for the management of HR+/HER2– breast cancer
• Assess emerging clinical trial and real-world evidence to gain practical insights into the appropriate use of oral SERD-based treatment strategies for patients with HR+/HER2– MBC
• Integrate clinical trial data, real-world evidence, and patient- and disease-specific factors to inform personalized treatment decisions for patients with HR+/HER2– MBC
• Apply evidence-based approaches to anticipate, monitor, and manage adverse effects associated with targeted therapies for patients with HR+/HER2– MBC

The staff of Physicians’ Education Resource^®, LLC, (PER^®) have no relevant financial relationships with ineligible companies.

PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Stemline Therapeutics, Inc.